Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants — 24 States, December 2024–April 2025

Respiratory syncytial virus (RSV) is a leading cause of intensive care unit (ICU) admission and respiratory failure among infants (children aged <1 year) in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, to protect against RSV-associated lower respiratory tract infection among all infants aged <8 months born during or entering their first RSV season. Following licensure, nirsevimab effectiveness has been demonstrated against RSV-associated infant hospitalization, but evidence regarding effectiveness against RSV-associated critical illness is limited. In a 27-hospital case-control investigation, nirsevimab effectiveness against both RSV-associated infant ICU admission and acute respiratory failure (illness requiring continuous positive airway pressure, bilevel positive airway pressure, or invasive mechanical ventilation) after hospital admission was evaluated during December 1, 2024-April 15, 2025. Among 457 case-patients who received a positive RSV test result and 302 control patients who received a negative RSV test result admitted to an ICU with respiratory symptoms, 14% and 45%, respectively, had received nirsevimab ≥7 days before symptom onset. Nirsevimab was 80% effective (95% CI = 70%-86%) against RSV-associated ICU admission and 83% effective (95% CI = 74%-90%) against acute respiratory failure when received a median of 52 days (IQR = 32-89 days) and 50 days (IQR = 32-86 days) before onset for each respective endpoint. These estimates support the recommendation for use of nirsevimab as a prevention strategy to protect infants against severe outcomes from RSV infection.

Authors

Publication Details

Journal
MMWR Morbidity and Mortality Weekly Report
Published
2025-11-20
DOI
https://doi.org/10.15585/mmwr.mm7437a1
Citations
1
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
1.35

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants — 24 States, December 2024–April 2025

Mary Stumpf, Satoshi Kamidani, Andrew R.J. Mitchell, Natasha Baig et al.
1 citations
MMWR Morbidity and Mortality Weekly Report
Respiratory viral infections research
1.35
article

Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants — 24 States, December 2024–April 2025

Mary Stumpf, Satoshi Kamidani, Andrew R.J. Mitchell, Natasha Baig, Kristina Betters, Janet R. Hume, Caroline Ciric, Masson Yates, Rebecca L. Douglas, Bria M. Coates, Tamara T. Bradford, Katherine Irby, Ariana Valenzuela, Ryan A. Nofziger, Chelsea C. Rohlfs, Regina M. Simeone, Colin T. Ackerman, Meghan Murdock, Natasha Halasa, Kathleen Chiotos, Lora Martin, Hillary Crandall, Nicole A. Twinem, Celibell Vargas, Aline B. Maddux, Melissa A. Cameron, Alexander H. Hogan, Amy J. Mathers, Scott L. Weiss, Anne Toivonen, Carlie Defelice, Mary Allen Staat, Katherine Lindsey, Laura D. Zambrano, Heather Anthony, Heather M. Kelley, Stephanie P. Schwartz, Joseph M. Majure, Laura S Stewart, Shira J. Gertz, Amanda Adler, Emily R. Levy, Christine A. Heisler, Gustavo Gavazzoni Blume, Adrienne G. Randolph, Judith A. Guzman‐Cottrill, Jigar Chauhan, Luis W Salazar, Melissa S. Stockwell, Michele Kong, Angela Campbell, Amanda B. Payne, Steven L. Shein, Christopher Crowley, Candice Colston, Lacy Malloch, Raul A. Silverio Francisco, Kelly N. Michelson, Allison Scott, Katherine W. Herbst, Lexi Petruccelli, Frances Zorensky, Amber O. Orzel-Lockwood, Ashlyn Madding, Michael Henne, Heidi Sauceda, Jemima M. Calixte, Jong-Ha C. Choi, Austin Biggs, Rebecca Clifford, Tracie C. Walker, Elizabeth Ricciardi, Jenny Bush, Alanah Mckelvey, Maygan Martin, Gabriella Ess, Ronald C. Sanders, Adriana Vasquez, Rachel M. Greer, Rajashri Rasal, Tom Connors, Olivia Kennedy, Mark D. Gonzalez, Meredith H. Lora, Jenna Lapira, Myooran Sivarupan, Eliana Rebolledo, Annika Conlee, Janelle J. Spencer-Ramirez, Berenice Marrufo, Glory Edioma, Taylor A. Slocumb, Zach Rusler, Chloe A Schluttner, Sarah Jae Wershil, Madeline Spradley
article en
1 citations

Abstract

Respiratory syncytial virus (RSV) is a leading cause of intensive care unit (ICU) admission and respiratory failure among infants (children aged <1 year) in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, to protect against RSV-associated lower respiratory tract infection among all infants aged <8 months born during or entering their first RSV season. Following licensure, nirsevimab effectiveness has been demonstrated against RSV-associated infant hospitalization, but evidence regarding effectiveness against RSV-associated critical illness is limited. In a 27-hospital case-control investigation, nirsevimab effectiveness against both RSV-associated infant ICU admission and acute respiratory failure (illness requiring continuous positive airway pressure, bilevel positive airway pressure, or invasive mechanical ventilation) after hospital admission was evaluated during December 1, 2024-April 15, 2025. Among 457 case-patients who received a positive RSV test result and 302 control patients who received a negative RSV test result admitted to an ICU with respiratory symptoms, 14% and 45%, respectively, had received nirsevimab ≥7 days before symptom onset. Nirsevimab was 80% effective (95% CI = 70%-86%) against RSV-associated ICU admission and 83% effective (95% CI = 74%-90%) against acute respiratory failure when received a median of 52 days (IQR = 32-89 days) and 50 days (IQR = 32-86 days) before onset for each respective endpoint. These estimates support the recommendation for use of nirsevimab as a prevention strategy to protect infants against severe outcomes from RSV infection.

MMWR Morbidity and Mortality Weekly ReportVol. 74(37)
Pfizer, Sanofi, Vanderbilt University, University of Minnesota, Moderna, Bavarian Nordic, Seqirus, National Institutes of Health, Centers for Disease Control and Prevention, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development
Openalex Percentile: Top 14%
Respiratory viral infections research
1.35
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.